| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
| Conditions: |
Restless Legs Syndrome,; Restless Legs,; Ekbom Syndrome |
| Intervention: |
Device: Venous Health Systems Vasculaire Leg Compression Device |
| Outcome Measures: |
The Restless Legs Syndrome Rating Scale; The Restless Legs Syndrome-Quality of Life Instrument (RLS-QLI); The Epworth Sleepiness Scale (ESS); The Johns Hopkins Restless Legs Severity Scale (JHRLS); The International Restless Legs Syndrome Rating Scale |
|
| 2 |
Not yet recruiting
|
Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital
| Condition: |
Agitation |
| Interventions: |
Drug: Ketamine; Drug: Haloperidol |
| Outcome Measures: |
Time from injection of drug to adequate sedation, defined as a score of 0 or less on the AMSS.; Number of participants intubated.; venous pH; serum potassium; Total time the participant is a patient in the Emergency Department.; Number of patients admitted versus number of patients discharged.; venous lactate; Number of patients experiencing laryngospasm.; Number of patients experiencing dystonia. |
|
| 3 |
Not yet recruiting
|
Effect of Deksmedetomidine and Remifentanil in Extubation Agitation
| Condition: |
Agitation |
| Interventions: |
Drug: deksmedetomidine; Drug: Remifentanil; Drug: Saline |
| Outcome Measures: |
To asses postoperative agitation score by Riker sedation agitation scale; Yo asses postoperative side effects emesis, vomitting or pain |
|
| 4 |
Unknown †
|
Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient
| Condition: |
Agitation |
| Interventions: |
Drug: Haloperidol; Drug: Midazolam |
| Outcome Measure: |
Time to sedation |
|
| 5 |
Recruiting
|
Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning
| Condition: |
Restlessness |
| Interventions: |
Drug: loxapine; Drug: Placebo |
| Outcome Measures: |
Weaning period; total duration of mechanical ventilation; incidence of unexpected extubations; clinical and biological respiratory parameters; incidence of mechanical ventilation related complications; incidence of adverse events, related and non related to the treatment; mortality rate; factors associated to weaning failure |
|
| 6 |
Recruiting
|
Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department
| Conditions: |
Agitation; Excited Delirium; Pain |
| Intervention: |
|
| Outcome Measures: |
Change in Altered Mental Status Score; Change in Visual Analog Scale Pain Score; Change in Serum Total Catecholamines; Length of Hospital Stay; Mortality; Complications; Change in Heart Rate; Change in Systolic Blood Pressure; Change in Mean Arterial Pressure; Disposition; Change in Body Temperature; Change in end tidal carbon dioxide; Change in Oxygen Saturation |
|
| 7 |
Recruiting
|
Reducing Agitation in People With Dementia: the Customized Activity Trial
| Condition: |
Dementia |
| Interventions: |
Behavioral: Tailored Activity Program; Other: Home Safety and Education Program |
| Outcome Measures: |
Frequency of Agitated Behavior in person with dementia; Frequency of agitated behaviors and quality of life in person with dementia; Caregiver wellbeing and time spent providing care; Cost effectiveness |
|
| 8 |
Unknown †
|
The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia
| Condition: |
Myringotomy |
| Intervention: |
Drug: Dexmedetomidine |
| Outcome Measures: |
Participant's Severity of Emergent Agitation (EA) using the Pediatric Anesthesia Emergence Delirium (PAED) scale in PACU (Post-Op Area).; Participant's Severity of Emergent Agitation (EA) in PACU (Post-Op Area) through Day 3 Post-Op using the Postanesthesia Discharge Scoring System (PADSS) score.; Participant's Severity of Emergent Agitation (EA) in PACU (Post-Op Area) through Day 3 Post-Op using the PADSS score. |
|
| 9 |
Recruiting
|
Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome
| Condition: |
Restless Leg Syndrome |
| Interventions: |
Drug: Gabapentin immediate release (Neurontin); Drug: Gabapentin enacarbil extended release (Horizant) |
| Outcome Measures: |
International Restless Leg Syndrome Rating Scale (IRLS); Restless Leg Syndrome Quality of Life Scale (RLSQoL) |
|
| 10 |
Recruiting
|
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
| Conditions: |
Agitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases |
| Intervention: |
Drug: Brexpiprazole, OPC-34712 |
| Outcome Measures: |
Change in the Cohen-Mansfield Agitation Inventory (CMAI) total score; Change in the Clinical Global Impression Severity of Illness (CGI-S) score, as related to symptoms of agitation |
|
| 11 |
Recruiting
|
A Study of Three Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
| Conditions: |
Agitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases |
| Intervention: |
Drug: Brexpiprazole, OPC-34712 |
| Outcome Measures: |
The primary outcome is the change in the Cohen-Mansfield Agitation Inventory (CMAI) total score; The secondary outcome is the change in the Clinical Global Impression-Severity of Illness (CGI-S) score, as related to symptoms of agitation |
|
| 12 |
Unknown †
|
Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy
| Conditions: |
Restless Leg Syndrome; Iron Deficiency Anemia |
| Intervention: |
Drug: ferric carboxymaltose |
| Outcome Measures: |
Primary endpoint: = 50% reduction of RLS symptoms as measured by International Restless Legs Study Group (IRLSS); Reduction of Periodic Limb Movements in Sleep (PLMS) ≥50% as measured with actimetry; Improvement of sleep according to the Pittsburgh Sleep Quality Questionnaire (PSQI); Improvement of sleepiness using Epworth Sleepiness Scale (ESS); Improvement of fatigue using Fatigue Severity Scale (FSS); Safety of ferric carboxymaltose during pregnancy in the 3rd trimester; Parameters of the newborn baby (apgar, umbilical artery pH, weight, mode of delivery) |
|
| 13 |
Unknown †
|
Treatment Routes for Exploring Agitation
| Conditions: |
Dementia; Behavior Problems |
| Interventions: |
Behavioral: TREA (Treatment Routes for Exploring Agitation); Behavioral: Placebo Control Group |
| Outcome Measures: |
Agitation Behavior Mapping Instrument (ABMI); affect/mood measured by Lawton's behavior stream assessment |
|
| 14 |
Recruiting
|
Dexmedetomidine to Prevent Agitation After Free Flap Surgery
| Conditions: |
Agitation; Delirium |
| Interventions: |
Drug: Dexmedetomidine; Drug: Saline placebo |
| Outcome Measures: |
agitation in PACU; postoperative delirium |
|
| 15 |
Recruiting
|
Can Acetaminophen Given 1-2 Hours to Children Before Ear Tube Surgery Reduce Agitation After Anesthesia?
| Conditions: |
Emergence Agitation; Pain |
| Intervention: |
Drug: Acetaminophen |
| Outcome Measures: |
Emergence Agitation; Pain |
|
| 16 |
Recruiting
|
Restless Leg Syndrome and Severe Preeclampsia
| Conditions: |
Restless Leg Syndrome; Severe Preeclampsia |
| Intervention: |
|
| Outcome Measure: |
Restless Leg Syndrome |
|
| 17 |
Unknown †
|
Neuroma Injections to Treat Restless Legs Syndrome - RCT
| Condition: |
Restless Legs Syndrome |
| Interventions: |
Drug: equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml; Drug: Normal saline - 1ml |
| Outcome Measure: |
International Restless Legs Rating Scale |
|
| 18 |
Recruiting
|
Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
| Condition: |
Restless Leg Syndrome |
| Interventions: |
Drug: incobotulinumtoxinA; Drug: Placebo |
| Outcome Measures: |
Restless Leg Syndrome Rating Scale; Epworth Sleep Scale |
|
| 19 |
Recruiting
|
Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome
| Conditions: |
Iron Deficiency; Restless Leg Syndrome |
| Interventions: |
Dietary Supplement: Probiotics; Dietary Supplement: Placebo |
| Outcome Measures: |
Change in Ferritin and CRP Levels; Restless Leg Questionnaire |
|
| 20 |
Unknown †
|
IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
| Conditions: |
Schizophrenia; Schizoaffective Disorder; Agitation |
| Interventions: |
Drug: IM olanzapine; Drug: haloperidol plus lorazepam IM |
| Outcome Measures: |
Positive and Negative Symptom Scale Excited Component (PANSS-EC); Agitation-Calmness Evaluation Scale (ACES) |
|
